These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35401204)

  • 1. C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis.
    Liu W; Zhang J; Xie T; Huang X; Wang B; Tian Y; Yuan Y
    Front Pharmacol; 2022; 13():855485. PubMed ID: 35401204
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity.
    Li L; Huang Z; Du K; Liu X; Li C; Wang D; Zhang Y; Wang C; Li J
    Front Pharmacol; 2022; 13():900699. PubMed ID: 35668930
    [No Abstract]   [Full Text] [Related]  

  • 3. SOX13 is a novel prognostic biomarker and associates with immune infiltration in breast cancer.
    Gao T; Jiang B; Zhou Y; He R; Xie L; Li Y
    Front Immunol; 2024; 15():1369892. PubMed ID: 38707897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response.
    Liu J; Bing Z; Wang J
    Front Genet; 2024; 15():1404348. PubMed ID: 39376739
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene
    Lin Y; Dong Y; Liu W; Fan X; Sun Y
    Int J Gen Med; 2022; 15():2501-2513. PubMed ID: 35282646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
    Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
    BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of the Oncogenic and Immunological Role of
    Ding J; Meng Y; Han Z; Luo X; Guo X; Li Y; Liu S; Zhuang K
    Front Oncol; 2022; 12():811567. PubMed ID: 35651805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysis.
    Zhu Z; Zhang W; Huo S; Huang T; Cao X; Zhang Y
    Front Mol Biosci; 2024; 11():1365655. PubMed ID: 38756529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 11. A systemic pan-cancer analysis of MPZL3 as a potential prognostic biomarker and its correlation with immune infiltration and drug sensitivity in breast cancer.
    Huang R; Li L; Wang Z; Shen K
    Front Oncol; 2022; 12():901728. PubMed ID: 35965540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Integrative Pan-Cancer Analysis Revealing LCN2 as an Oncogenic Immune Protein in Tumor Microenvironment.
    Xu WX; Zhang J; Hua YT; Yang SJ; Wang DD; Tang JH
    Front Oncol; 2020; 10():605097. PubMed ID: 33425761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Integrative Pan-Cancer Analysis of PBK in Human Tumors.
    Wen H; Chen Z; Li M; Huang Q; Deng Y; Zheng J; Xiong M; Wang P; Zhang W
    Front Mol Biosci; 2021; 8():755911. PubMed ID: 34859049
    [No Abstract]   [Full Text] [Related]  

  • 16. Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy.
    Liu Y; Tu M; Wang L
    Int J Gen Med; 2022; 15():2171-2185. PubMed ID: 35241932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1QTNF6 as a novel biomarker regulates cellular behaviors in A549 cells and exacerbates the outcome of lung adenocarcinoma patients.
    Han M; Wang B; Zhu M; Zhang Y
    In Vitro Cell Dev Biol Anim; 2019 Sep; 55(8):614-621. PubMed ID: 31292940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer analysis of the prognostic and immunological role of SNX29: a potential target for survival and immunotherapy.
    Xu C; Li F; Liu Z; Yan C; Xiao J
    BMC Med Genomics; 2023 Feb; 16(1):34. PubMed ID: 36829159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pan-Cancer Crosstalk Between the
    Xie R; Yuan M; Jiang Y
    Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
    [No Abstract]   [Full Text] [Related]  

  • 20. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
    Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
    Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.